Sensus Healthcare (NASDAQ:SRTS) Posts Earnings Results

Sensus Healthcare (NASDAQ:SRTS) posted its quarterly earnings results on Thursday. The company reported ($0.16) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.04 by ($0.20), Zacks reports. The firm had revenue of $8.34 million for the quarter, compared to analyst estimates of $7.23 million. Sensus Healthcare had a net margin of 15.90% and a return on equity of 12.60%.

Sensus Healthcare Trading Down 4.3%

SRTS stock opened at $4.46 on Friday. The firm has a market cap of $73.57 million, a P/E ratio of 11.15 and a beta of 1.30. Sensus Healthcare has a 12-month low of $4.01 and a 12-month high of $9.33. The stock’s 50 day simple moving average is $4.61 and its 200 day simple moving average is $6.12.

Analyst Upgrades and Downgrades

Several research firms recently issued reports on SRTS. HC Wainwright reissued a “buy” rating and set a $12.00 price target on shares of Sensus Healthcare in a research report on Friday, April 4th. Lake Street Capital dropped their price target on Sensus Healthcare from $18.00 to $13.00 and set a “buy” rating on the stock in a research report on Tuesday, March 11th.

Sensus Healthcare Company Profile

Sensus Healthcare, Inc, a medical device company, manufactures and sells radiation therapy devices to healthcare providers worldwide. The company uses superficial radiation therapy, a low-energy X-ray technology in its portfolio of treatment devices. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers, including basal cell and squamous cell skin cancers, as well as other skin conditions, such as keloids; and SRT-100 Vision, which provides the user with a superficial radiation therapy-tailored treatment planning application that integrates an embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters.